Axonal degeneration and progressive neurologic disability in multiple sclerosis

Neurotoxicity Research

Volumn 5, Issue 1-2, 2003, Pages 157-164

  Bjartmar, Carl ^a   Trapp, Bruce D ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Axonal degeneration; Demyelination; Inflammation; Remyelination

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; APOMORPHINE; DOPAMINE 1 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ISOQUINOLINE DERIVATIVE; NEUROTOXIN; SALSOLINOL; SPIPERONE; TETRAHYDROISOQUINOLINE DERIVATIVE;

ANIMAL; ANIMAL BEHAVIOR; ARTICLE; BINDING COMPETITION; C57BL MOUSE; CATALEPSY; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; MALE; MOTOR ACTIVITY; MOUSE;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ANIMALS; APOMORPHINE; BEHAVIOR, ANIMAL; BINDING, COMPETITIVE; CATALEPSY; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; ISOQUINOLINES; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; NEUROTOXINS; RECEPTORS, DOPAMINE D1; SPIPERONE; TETRAHYDROISOQUINOLINES;

EID: 0642345898     PISSN: 10298428     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03033380     Document Type: Article

References (62)

1. Anzini P, DH Neuberg, M Schachner, E Nelles, K Willecke, J Zielasek, KV Toyka, U Suter and R Martini (1997) Structural abnormalities and deficient maintenance of peripheral nerve myelin in mice lacking the gap junction protein connexin 32. J. Neurosci. 17, 4545-4551.
2. Arnold DL, GT Reiss, PM Matthews, GS Francis, DL Collins, C Wolfson and JP Antel (1994) Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis. Ann. Neurol. 36, 76-82.
3. Barnes D, PMG Munro, BD Youl, JW Prineas and WI McDonald (1991) The longstanding MS lesion. Brain 114, 1271-1280.
4. Bjartmar C and BD Trapp (2001) Axonal and neuronal degeneration in multiple sclerosis: Mechanisms and functional consequences. Curr. Opin. Neurol. 14, 271-278.
5. Bjartmar C, X Yin and BD Trapp (1999) Axonal pathology in myelin disorders. J. Neurocytol. 28, 383-395.
6. Bjartmar C, G Kidd, S Moörk, R Rudick and BD Trapp (2000) Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann. Neurol. 48, 893-901.
7. Bjartmar C, RP Kinkel, G Kidd, RA Rudick and BD Trapp (2001a) Axonal loss in normal-appearing white matter in a patient with acute MS. Neurology 57, 1248-1252.
8. Bjartmar C, J Battistuta, N Terada, E Dupree and BD Trapp (2001b) N-acetyl aspartate is an axon specific marker of mature white matter in vivo: A biochemical and immunohistochemical study on the rat optic nerve. Ann. Neurol. 51, 51-58.
9. Bjartmar C, G Kidd and Ransohoff (2001c) A real-time insight into disease progression and the role of axonal injury in multiple sclerosis. Arch. Neurol. 58, 37-39.
10. Charcot M (1868) Histologie de le sclerose en plaques. Gazette Hopitaux 141, 554-558.
11. Clark JB (1998) N-acetyl aspartate: A marker for neuronal loss or mitochondrial dysfunction. Dev. Neurosci. 20, 271-276.
12. Confavreux C, S Vukusic, T Moreau and P Adeleine (2000) Relapses and progression of disability in multiple sclerosis. N. Engl. J. Med. 343, 1430-1438.
13. Davie CA, GJ Barker, S Webb, PS Tofts, AJ Thompson, AE Harding, WI McDonald and DH Miller (1995) Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. Brain 118, 1583-1592.
14. De Stefano N, PM Matthews and DL Arnold (1995) Reversible decreases in N-acetylaspartate after acute brain injury. Magn. Reson. Med. 34, 721-727.
15. De Stefano N, PM Matthews, L Fu, S Narayanan, J Stanley, GS Francis, JP Antel and DL Arnold (1998) Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain 121, 1469-1477.
16. Evangelou N, MM Esiri, S Smith, J Palace and PM Matthews (2000) Quantitative pathological evidence for axonal loss in normal appearing white matter in multiple sclerosis. Ann. Neurol. 47, 391-395.
17. Ferguson B, MK Matyszak, MM Esiri and VH Perry (1997) Axonal damage in acute multiple sclerosis lesions. Brain 120 393-399.
18. Filippi M, B Colombo, M Rovaris, C Pereira, V Martinelli and G Comi (1997) A longitudinal magnetic resonance imaging study of the cervical cord in multiple sclerosis. J. Neuroimaging 7, 78-80.
19. Fu L, PM Matthews, N De Stefano, KJ Worsley, S Narayanan, GS Francis, JP Antel, C Wolfson and DL Arnold (1998) Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain 121, 103-113.
20. Ganter P, C Prince and MM Esiri (1999) Spinal cord axonal loss in multiple sclerosis: A post-mortem study. Neuropathol. Appl. Neurobiol. 25, 459-467.
21. 0 gene disruption leads to hypomyelination, abnormal expression of recognition molecules, and degeneration of myelin and axons. Cell 71, 565-576.
22. Gonen O, I Catalaa, JS Babb, Y Ge, LJ Mannon, DL Kolson and RI Grossman (2000) Total brain N-acetylaspartate. A new measure of disease load in MS. Neurology 54, 15-19.
23. Graham GD, AM Blamire, AM Howseman, DL Rothman, PB Fayad, LM Brass, OA Petroff, RG Shulman and JW Prichard (1992) Proton magnetic resonance spectroscopy of cerebral lactate and other metabolites in stroke patients. Stroke 23, 333-340.
24. Griffiths I, M Klugmann, T Anderson, D Yool, C Thomson, MH Schwab, A Schneider, F Zimmermann, M McCulloch, N Nadon and K-A Nave (1998) Axonal swellings and degeneration in mice lacking the major proteolipid of myelin. Science 280, 1610-1613.
25. Holfeld R (1997) Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. Brain 120, 865-916.
26. Kidd D, JW Thorpe, AJ Thompson, BE Kendall, IF Mosley, DG MacManus, WI McDonald and DH Miller (1993) Spinal cord MRI using multi-array coils and fast spin echo. II. Findings in multiple sclerosis. Neurology 43, 2632-2637.
27. Kidd D, F Barkhof, R McConnell, PR Algra, IV Allen and T Revesz (1999) Cortical lesions in multiple sclerosis. Brain 122, 17-26.
28. Koo EH, SS Sisodia, DR Archer, LJ Martin, A Weidemann, K Beyreuther, P Fischer, CL Masters and DL Price (1990) Precursor of amyloid protein in Alzheimer disease undergoes fast anterograde axonal transport. Proc. Natl. Acad. Sci. USA 87, 1561-1565.
29. Kornek B and H Lassman (1999) Axonal pathology in multiple sclerosis. A historical note. Brain Pathol. 9, 651-656.
30. Lee MA, AM Blamire, S Pendlebury, KH Ho, KR Mills, P Styles, J Palace and PM Matthews (2000) Axonal injury or loss in the internal capsule and motor impairment in multiple sclerosis. Arch. Neurol. 57, 65-70.
31. Losseff NA, SL Webb, JI O'Riordan, R Page, L Wang, GJ Barker, PS Tofts, WI McDonald, DH Miller and AJ Thompson (1996a) Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 119, 701-708.
32. Losseff NA, L Wang, HM Lai, DS Yoo, ML Gawne-Cain, WI McDonald, DH Miller and AJ Thompson (1996b) Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain 119, 2009-2019.
33. Lovas G, N Szilagyi, K Majtenyi, M Palkovits and S Komoly (2000) Axonal changes in chronic demyelinated cervical spinal cord plaques. Brain 123, 308-317.
34. Matthews PM, E Pioro, S Narayanan, N De Stefano, L Fu, G Francis, J Antel, C Wolfson and DL Arnold (1996) Assessment of lesion pathology in multiple sclerosis using quantitative MRI morphometry and magnetic resonance spectroscopy. Brain 119, 715-722.
35. Matthews PM, N De Stefano, S Narayanan, GS Francis, JS Wolinsky, JP Antel and DL Arnold (1998) Putting magnetic resonance spectroscopy studies in context: Axonal damage and disability in multiple sclerosis. Semin. Neurol. 18, 327-336.
36. McFarland HF, JA Frank, PS Albert, ME Smith, R Martin, JO Harris, N Patronas, H Maloni and DE McFarlin (1992) Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann. Neurol. 32, 758-766.
37. Mews I, M Bergmann, S Bunkowski, F Gullotta and W Brück (1998) Oligodendrocyte and axon pathology in clinically silent multiple sclerosis lesions. Multiple Sclerosis, 4, 55-62.
38. Moffett JR, MAA Namboodiri, CB Cangro and JH Neale (1991) Immunohistochemical localization of N-acetylaspartate in rat brain. Neuroreport 2, 131-134.
39. Narayanan S, L Fu, E Pioro, N De Stefano, DL Collins, G Francis, JP Antel, PM Matthews and DL Arnold (1997) Imaging of axonal damage in multiple sclerosis: Spatial distribution, of magnetic resonance imaging lesions. Ann. Neurol. 41, 385-391.
40. Narayana PA, TJ Doyle, L Dejian and JS Wolinsky (1998) Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis. Ann. Neurol. 43, 56-71.
41. Noseworthy JH, C Luccinetti, M Rodriquez and BG Weinshenker (2000) Multiple sclerosis. N. Engl. J. Med. 343, 938-952.
42. Patel TB and JB Clark (1979) Synthesis of N-acetyl-L-aspartate by rat brain mitochondria and involvement in mitochondrial/cytosolic carbon transport. Biochem. J. 184, 539-546.
43. Peterson JW, L Bö, S Mörk, A Chang and BD Trapp (2001) Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann. Neurol. 50, 389-400.
44. Pioro E, JP Antel, NR Cashman and DL Arnold (1994) Detection of cortical neuron loss in motor neuron disease by proton magnetic resonance spectroscopic imaging in vivo. Neurology 44, 1933-1938.
45. Pitt D, P Werner and CS Raine (2000) Glutamate excitotoxicity in a model of multiple sclerosis. Nature Med. 6, 67-70.
46. Reddy H, S Narayanan, R Arnoutelis, M Jenkinson, J Antel, PM Matthews and DL Arnold (2000) Evidence for adaptive functional changes in the cerebral cortex with axonal injury from multiple sclerosis. Brain 123, 2314-2320.
47. Rudick RA, JA Cohen, B Weinstock-Guttman, RP Kinkel and RM Ransohoff (1997) Management of multiple sclerosis. N. Engl. J. Med. 337, 1604-1611.
48. Rudick RA, E Fisher, JC Lee, J Simon and L Jacobs (1999a) Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 53, 1698-1704.
49. Rudick RA, A Goodman, RM Herndon and HS Panitch (1999b) Selecting relapsing remitting multiple sclerosis patients for treatment: The case for early treatment. J. Neuroimmunol. 98, 22-28.
50. Sahenk Z, L Chen and JR Mendell (1999) Effects of PMP22 duplication and deletions on the axonal cytoskeleton. Ann. Neurol. 45, 16-24.
51. Scherer S (1999) Axonal pathology in demyelinating diseases. Ann. Neurol. 45, 6-7.
52. Simmons ML, CG Frondoza and JT Coyle (1991) Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience 45, 37-45.
53. Simon JH, LD Jacobs, MK Campion, RA Rudick, DL Cookfair, RM Herndon, JR Richert, AM Salazar, JS Fisher, DE Goodkin, N Simonian, M Lajaunie, DE Miller, K Wende, A Martens-Davidson, RP Kinkel, FE Munschauer, CM Brownscheidle and The Multiple Sclerosis Collaborative Research Group (MSCRG) (1999) A longitudinal study of brain atrophy in relapsing multiple sclerosis. Neurology 53, 139-148.
54. Simon, JH, RP Kinkel, L Jacobs, L Bub and N Simonian (2000) A Wallerian degeneration pattern in patients at risk for MS. Neurology 54, 1155-1160.
55. Stevenson VL and DH Miller (1999) Magnetic resonance imaging in the monitoring of disease progression in multiple sclerosis. Multiple Sclerosis 5, 268-272.
56. Trapp BD, J Peterson, RM Ransohoff, R Rudick, S Mörk and L Bö (1998) Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338, 278-285.
57. Trapp BD, RM Ransohoff, E Fisher and RA Rudick (1999) Neurodegeneration in multiple sclerosis: Relationship to neurological disability. Neuroscientist 5, 48-57.
58. Truckenmiller ME, MAA Namboodiri, MJ Brownstein and JH Neale (1985) N -acetylation of L-aspartate in the nervous system: Differential distribution of a specific enzyme. J. Neurochem. 45, 1658-1662.
59. de Waegh SM, VM-Y Lee and ST Brady (1992) Local modulation of neurofilament phosphorylation, axonal caliber, and slow axonal transport by myelinating Schwann cells. Cell 68, 451-463.
60. van Waesberghe JHTM, W Kamphorst, CJA De Groot, MAA van Walderveen, JA Castelijns, R Ravid, GJ Lycklama a Nijeholt, P van der Valk, CH Polman, AJ Thompson and F Barkhof (1999) Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability. Ann. Neurol. 46, 747-754.
61. Waxman SG (1998) Demyelinating diseases - new pathological insights, new therapeutic targets. N. Engl. J. Med. 338, 223-225.
62. Yin X, TO Crawford, JW Griffin, P Tu, VM-Y Lee, C Li, J Roder and BD Trapp (1998) Myelin-associated glycoprotein is a myelin signal that modulates the caliber of myelinated axons. J. Neurosci. 18, 1953-1962.